主页 > 医学新闻 >
【medical-news】Dynamic contrast-enhanced magnetic resonanc
Dynamic contrast-enhanced magnetic resonance helps spot prostate cancer
11/14/2006
By: Reuters Health
NEW YORK (Reuters Health), Nov 14 - Both dynamic contrast-enhanced magnetic resonance (MR) imaging and 3D MR spectroscopic imaging do better than T2-weighted MR in pinpointing prostate cancer, Dutch researchers report in the November issue of Radiology.
"Accurate prostate cancer localization is of great importance in patients with increasing prostate specific antigen -- PSA -- levels and repetitive MR-negative biopsies," lead investigator Dr. Jurgen J. Futterer told Reuters Health.
However, Dr. Futterer and colleagues at Radboud University, Nijmegen note that among difficulties in such localization are that benign prostatic hyperplasia has a signal density similar to that of cancer.
To investigate the utility of dynamic contrast-enhanced MR imaging and 3D MR spectroscopic imaging in improving results, the researchers studied 34 patients with a mean PSA level of 8 ng/mL. Their median biopsy Gleason score was 6.
Two radiologists with different levels of experienced examined the images obtained with these methods and with T2-weighted MR.
Reader accuracy in tumor localization with dynamic contrast-enhanced imaging was significantly better than that with quantitative spectroscopic imaging.
Moreover, results with both dynamic contrast-enhanced imaging and spectroscopic imaging were significantly better than that with T2-weighted imaging.
Given these findings, the researchers concluded that "if these advanced techniques are included in the MR imaging protocol, the localization of prostate cancer in patients will improve."
By David Douglas
Last Updated: 2006-11-13 14:40:10 -0400 (Reuters Health) 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Dynamic contrast-enhanced magnetic resonance helps spot prostate cancer
11/14/2006
By: Reuters Health
动态对比增强核磁共振显象在细小前列腺癌方面的优势‘
11/14/2006
来自：Reuters Health杂志
NEW YORK (Reuters Health), Nov 14 - Both dynamic contrast-enhanced magnetic resonance (MR)
imaging and 3D MR spectroscopic imaging do better than T2-weighted MR in pinpointing prostate cancer, Dutch researchers report in the November issue of Radiology
纽约（Reuters Health杂志）11月14日，荷兰研究员在11月的放射学杂志上报道，动态对比增强核磁共振显象和3D核磁共振分光显象比T2加权核磁共振在发现细小前列腺癌方面具有优势
Accurate prostate cancer localization is of great importance in patients with increasing prostate specific antigen -- PSA -- levels and repetitive MR-negative biopsies," lead investigator Dr. Jurgen J. Futterer told Reuters Health.
利用前列腺特异抗体－PSA的浓度水平的升高和反复的MR-阴性活检来精确定位患者的前列腺癌部位是很重要的，首席研究员Dr. Jurgen J. Futterer告诉Reuters Health.杂志。
However, Dr. Futterer and colleagues at Radboud University, Nijmegen note that among difficulties in such localization are that benign prostatic hyperplasia has a signal density similar to that of cancer.
尽管如此，Dr. Futterer和他在Radboud大学的同事Nijmegen说在定位前列腺癌的众多困难中，与前列腺癌有相似信号密度的良性的前列腺增生也是中间一个。
To investigate the utility of dynamic contrast-enhanced MR imaging and 3D MR spectroscopic imaging in improving results, the researchers studied 34 patients with a mean PSA level of 8 ng/mL. Their median biopsy Gleason score was 6.
为了研究动态对比增强核磁共振显象和3D核磁共振分光显象在改良结果方面的应用，研究人员调查了34个平均PSA水平为8 ng/mL的病号。他们间接活检Gleason 指标为6。
Two radiologists with different levels of experienced examined the images obtained with these methods and with T2-weighted MR.
两个拥有不同经验的放射学家分析了通过这些方法和T2加权核磁共振显象得到的图象
Reader accuracy in tumor localization with dynamic contrast-enhanced imaging was significantly better than that with quantitative spectroscopic imaging.
用动态对比增强核磁共振显象技术得到的肿瘤的精确定位和用定量分光显象相比颇具优势。
Moreover, results with both dynamic contrast-enhanced imaging and spectroscopic imaging were significantly better than that with T2-weighted imaging.
并且，同时运用动态对比增强核磁共振显象和分光显象比用T2加权核磁共振显象优势很明显。
Given these findings, the researchers concluded that "if these advanced techniques are included in the MR imaging protocol, the localization of prostate cancer in patients will improve."
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-04 05:11
医学,生命科学网